Low-viscosity antigen binding proteins and methods of making them
AssigneeAmgen Inc.
InventorsJoon Hoi HUH, Riki STEVENSON, Pavel BONDARENKO, Andrew NICHOLS, Da REN, Neeraj Jagdish AGRAWAL, Richard SMITH
Life of this patent
Estimating the term…
Loading patent…
AssigneeAmgen Inc.
InventorsJoon Hoi HUH, Riki STEVENSON, Pavel BONDARENKO, Andrew NICHOLS, Da REN, Neeraj Jagdish AGRAWAL, Richard SMITH
Estimating the term…
The present invention concerns a method for preparing antigen binding proteins specific for PCSK9 with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
A method of reducing the viscosity of an antigen binding protein specific for PCSK9, which comprises making one or more modifications in the sequence of the antigen binding protein selected from:
An antigen binding protein that specific for PCSK9, which comprises one or more sequence modifications selected from:
An antigen binding protein that specifically binds PCSK9 comprising the heavy and light chain sequences of a PCSK-9 binding polypeptide except that said antigen binding protein comprises a set of substitutions selected from FIG. 10:
The antigen binding protein of claim 55 wherein the antigen binding protein of claim 88 reaches maximum serum concentration at least about twice as fast as the parental antibody.
The antigen binding protein of claim 55 wherein the antigen binding protein of claim 88 reaches a maximum serum concentration that is at least about 25% higher than that of the parental antibody.
A method of preparing an antigen binding protein that reaches a higher maximum serum concentration than does a parental antibody and reaches the maximum serum concentration faster than does a parental antibody when both are administered at the same concentration, which comprises introducing sequence modification 440X16 in the parental antibody wherein X16 is selected from R, K, and H.
Dependencies are inferred from the claim text.